Market Overview

UPDATE: Deutsche Bank Upgrades Tenet Healthcare to Buy on Compelling Outlook

Related THC
Top 4 Mid-Cap Stocks In The Hospitals Industry With The Highest ROI
Tenet Healthcare Extends Contract with Humana to Drive Growth

Deutsche Bank raised its rating on Tenet Healthcare (NYSE: THC) from Hold to Buy and increased its price target from $31 to $38.

Deutsche Bank noted, "Our upgrade is underpinned by: (1) clear signs of improving business mix and margins due especially to gains in outpatient, (2) tangible momentum in Conifer, and (3) a more sustainable FCF profile going forward. We also continue to highlight the upside risks due to PPACA, and note our 2014 EPS of $3.85 is 17% above consensus. Due to a more favorable outlook, we believe THC should be positioned to garner an in-line (~6x) fwd EV/EBITDA multiple."

Tenet Healthcare closed at $30.63 on Thursday.

Posted-In: Deutsche BankAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (THC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free